TUSK's Q3 report breaks down the deal activity, valuation trends, and forces shaping the dermatology market.
Fill out the form to access the full report.
Your information is never shared. TUSK represents practice owners exclusively.
Q3 2026 Dermatology M&A Market Report
What's inside the report
Executive Summary
The quarter at a glance: market momentum, the widening valuation spread, and what a more disciplined buyer environment means for owners considering a sale.
State of the Industry
Why dermatology held up while broader physician-services M&A pulled back, and how a smaller, fragmented field concentrates buyer demand on quality practices.
The Second Bites Wave
How the private equity hold clock is putting fresh capital and more funded buyers back in the market, all competing for a limited pool of strong practices.
Regulatory Headwinds
What Oregon SB 951, California SB 351, and pending bills in nine or more states mean for where buyers will transact and how deals must be structured.
Deal Structure & Valuation
The six components behind every offer, from cash at close to rollover equity, and why structure often matters more than the headline multiple.
Key Findings & 2026 Outlook
The takeaways that matter most, plus the two opposing forces that will define dermatology dealmaking through the rest of the year.